- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Additional file 1 of A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027
Description
Additional file 1 : Additional methods (patient inclusion and exclusion criteria, EGFR mutation detection, statistical considerations), Additional Fig. 1 (patient disposition), Additional Fig. 2 (individual patient best overall response in the safety analysis set [n = 38]. Shown is a waterfall plot of maximum tumour reduction from baseline assessed according to RECIST version 1.1 criteria in 36 patients. Confirmation of response could not be obtained for two non-evaluable patients, one with no evaluable target lesion and one with confirmed progressive disease due to a new brain metastasis), Additional Fig. 3 (Kaplan–Meier survival analysis by EGFR mutation type in the full analysis set [n = 37]. (A) Progression-free survival [PFS]. (B) Overall survival [OS]. (C) Time to treatment failure [TTF]).
Related Articles
See more- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1871710641493869184
-
- Data Source
-
- OpenAIRE